Publication Name	World Journal of Virology
Manuscript ID	80004
Country	Iran

Received	2022-09-13 19:19
Peer-Review Started	2022-09-13 19:21
To Make the First Decision
Return for Revision	2022-10-01 19:09
Revised	2022-10-08 06:50
Second Decision	2022-10-24 03:56
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-10-28 21:43
Articles in Press	2022-10-28 21:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-11-10 00:57
Publish the Manuscript Online	2022-11-23 13:56

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Potential risk of liver injury in epileptic patients during COVID-19 pandemic
Manuscript Source	Invited Manuscript
All Author List	Nasim Tabrizi and Athena Sharifi-Razavi
ORCID	Author(s) ORCID Number Nasim Tabrizi http://orcid.org/0000-0001-7978-2014 Athena Sharifi-Razavi http://orcid.org/0000-0003-3861-9741
Funding Agency and Grant Number
Corresponding Author	Athena Sharifi-Razavi, MD, Assistant Professor, Department of Neurology, Mazandaran University of Medical Sciences, Bou Ali Sina Hospital, Pasdaran Boulevard, Sari 4815838477, Iran. athena.sharifi@yahoo.com
Key Words	COVID-19; Epilepsy; Seizure; Drug induced liver injury; Corona virus; Hepatic failure
Core Tip	Most of antiseizure medications (ASMs) are metabolized in liver and many of them particularly first-generation ASMs have the potential to increase liver enzymes or induce liver injury. Hence, treatment of new onset seizures or epilepsy by ASMs during the course of coronavirus disease 2019 (COVID-19), which could potentially be complicated by hepatic dysfunction, is a challenging clinical issue. In this review, we aimed to discuss the potential risks of liver injury in patients with COVID-19 who are under treatment for epilepsy or need to receive ASMs to subside acute symptomatic seizures.
Publish Date	2022-11-23 13:56
Citation	Tabrizi N, Sharifi-Razavi A. Potential risk of liver injury in epileptic patients during COVID-19 pandemic. World J Virol 2022; 11(6): 467-476
URL	https://www.wjgnet.com/2220-3249/full/v11/i6/467.htm
DOI	https://dx.doi.org/10.5501/wjv.v11.i6.467

Full Article (PDF)	WJV-11-467.pdf
Full Article (Word)	WJV-11-467.docx
Manuscript File	80004_Auto_Edited-LM.docx
Answering Reviewers	80004-Answering reviewers.pdf
Audio Core Tip	80004-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	80004-Conflict-of-interest statement.pdf
Copyright License Agreement	80004-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	80004-Language certificate.pdf
Peer-review Report	80004-Peer-review(s).pdf
Scientific Misconduct Check	80004-Bing-Fan JR-2.png
Scientific Editor Work List	80004-Scientific editor work list.pdf
CrossCheck Report	80004-CrossCheck report.pdf
CrossCheck Report	80004-CrossCheck.png